Sirukumab治疗类风湿关节炎:III期SIRROUND-D研究
SIRROUND-D是一项III期多中心随机双盲安慰剂对照平行组研究,纳入1670例对改善病情抗风湿药反应不足的活动性RA患者,评估Sirukumab(选择性结合IL-6细胞因子的人单克隆抗体)的疗效与安全性。结果显示,Sirukumab 100 mg每2周或50 mg每4周在第16周ACR20应答率和第52周改良Sharp/van der Heijde评分进展均显著优于安慰剂,所有主要次要终点均达到。
要点
- Sirukumab 100 mg每2周和50 mg每4周在第16周ACR20应答率均显著高于安慰剂。
- 第52周改良Sharp/van der Heijde评分进展显著低于安慰剂。
- 常见不良事件包括肝酶升高、上呼吸道感染、注射部位红斑和鼻咽炎。
核心结论
- Sirukumab 100 mg每2周和50 mg每4周可显著减轻RA症状、抑制结构损伤进展并改善躯体功能和生活质量,安全性符合预期。
研究设计与样本
- III期多中心随机双盲安慰剂对照平行组研究,1670例对改善病情抗风湿药反应不足的活动性RA患者按1:1:1随机接受Sirukumab 100 mg每2周、50 mg每4周或安慰剂每2周皮下注射,报告至第52周结果。
主要发现
- 第16周ACR20应答率:Sirukumab 100 mg每2周组53.5%、50 mg每4周组54.8%,安慰剂组26.4%(两项p<0.001)。
- 第52周改良Sharp/van der Heijde评分较基线平均变化:100 mg每2周组0.46(SD 3.26)、50 mg每4周组0.50(SD 2.96),安慰剂组3.69(SD 9.25)(两项p<0.001)。
- 所有主要次要终点均达到,包括第24周HAQ-DI较基线变化、ACR50应答、基于CRP的DAS28和主要临床应答(至第52周连续6个月ACR70)。
- Sirukumab最常见不良事件为肝酶升高、上呼吸道感染、注射部位红斑和鼻咽炎。
临床怎么用
- 对于对改善病情抗风湿药反应不足的活动性RA患者,Sirukumab 100 mg每2周或50 mg每4周皮下注射可作为抑制结构损伤进展和改善症状及功能的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology. Unlike IL-6 receptor inhibitors, sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine. The phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group SIRROUND-D study (ClinicalTrials.gov identifier NCT01604343) evaluated the efficacy and safety of sirukumab in patients with active RA refractory to disease-modifying antirheumatic drugs. METHODS: Patients were randomised 1:1:1 to treatment with sirukumab 100 mg every 2 weeks, 50 mg every 4 weeks or placebo every 2 weeks subcutaneously. Results through week 52 are reported. RESULTS: Of 1670 randomised patients, significantly more patients achieved American College of Rheumatology 20% (ACR20) response at week 16 (coprimary endpoint) with sirukumab 100 mg every 2 weeks (53.5%) or 50 mg every 4 weeks (54.8%) versus placebo (26.4%; both p<0.001). Mean (SD) change from baseline in modified Sharp/van der Heijde score at week 52 (coprimary endpoint) was significantly lower with sirukumab (100 mg every 2 weeks: 0.46 (3.26); 50 mg every 4 weeks: 0.50 (2.96)) versus placebo (3.69 (9.25); both p<0.001). All major secondary endpoints (week 24 Health Assessment Questionnaire-Disability Index change from baseline, ACR50 response, 28-joint Disease Activity Score based on C reactive protein and major clinical response (ACR70 for six continuous months by week 52)) were met. The most common adverse events with sirukumab were elevated liver enzymes, upper respiratory tract infection, injection site erythema and nasopharyngitis. CONCLUSIONS: Sirukumab 100 mg every 2 weeks and 50 mg every 4 weeks led to significant reductions in RA symptoms, inhibition of structural damage progression and physical function and quality of life improvements, with an expected safety profile. TRIAL REGISTRATION NUMBER: NCT01604343; Results.
引用
- Takeuchi T, Thorne C, Karpouzas G, et al. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann Rheum Dis. 2017. PMID: 28855173. doi:10.1136/annrheumdis-2017-211328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。